RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma

      한글로보기

      https://www.riss.kr/link?id=A106490582

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      The abscopal effect is a term that has been used to describe the phenomenon in which localized radiation therapy treatment of a tumor lesion triggers a spontaneous regression of metastatic lesion(s) at a non-irradiated distant site(s). Radiation thera...

      The abscopal effect is a term that has been used to describe the phenomenon in which localized radiation therapy treatment of a tumor lesion triggers a spontaneous regression of metastatic lesion(s) at a non-irradiated distant site(s). Radiation therapy induced abscopal effects are believed to be mediated by activation and stimulation of the immune system. However, due to the brain’s distinctive immune microenvironment, extracranial abscopal responses following cranial radiation therapy have rarely been reported. In this report, we describe the case of 42-year-old female patient with metastatic melanoma who experienced an abscopal response following her cranial radiation therapy for her brain metastasis. The patient initially presented with a stage III melanoma of the right upper skin of her back. Approximately 5 years after her diagnosis, the patient developed a large metastatic lesion in her upper right pectoral region of her chest wall and axilla. Since the patient’s tumor was positive for BRAF and MEK, targeted therapy with dabrafenib and trametinib was initiated. However, the patient experienced central nervous system (CNS) symptoms such as headache and disequilibrium and developed brain metastases prior to the start of targeted therapy. The patient received radiation therapy to a dose of 30 Gy delivered in 15 fractions to her brain lesions while the patient was on dabrafenib and trametinib therapy.
      The patient’s CNS metastases improved significantly within weeks of her therapy. The patient’s non-irradiated large extracranial chest mass and axilla mass also shrank substantially demonstrating the abscopal effect during her CNS radiation therapy. Following radiation therapy of her residual chest lesions, the patient was disease free clinically and her CNS lesions had regressed. However, when the radiation therapy ended and the patient continued her targeted therapy alone, recurrence outside of her previously treated fields was noted. The disease recurrence could be due to the possibility of developing BRAF resistance clones to the BRAF targeted therapy. The patient died eventually due to wide spread systemic disease recurrence despite targeted therapy

      더보기

      참고문헌 (Reference)

      1 Mole RH, "Whole body irradiation; radiobiology or medicine?" 26 : 234-241, 1953

      2 Ngwa W, "Using immunotherapy to boost the abscopal effect" 18 : 313-322, 2018

      3 Moriceau G, "Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction" 27 : 240-256, 2015

      4 Park B, "The effect of radiation on the immune response to cancers" 15 : 927-943, 2014

      5 Abuodeh Y, "Systematic review of case reports on the abscopal effect" 40 : 25-37, 2016

      6 Ishiyama H, "Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?" 10 : 196-198, 2012

      7 Okwan-Duodu D, "Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma" 38 : 119-125, 2015

      8 Eric C. Ko, "Radiotherapy and checkpoint inhibitors: a winning new combination?" SAGE Publications 10 : 175883591876824-, 2018

      9 Negi N, "Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ" 37 : 57-68, 2018

      10 Weber JS, "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial" 16 : 375-384, 2015

      1 Mole RH, "Whole body irradiation; radiobiology or medicine?" 26 : 234-241, 1953

      2 Ngwa W, "Using immunotherapy to boost the abscopal effect" 18 : 313-322, 2018

      3 Moriceau G, "Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction" 27 : 240-256, 2015

      4 Park B, "The effect of radiation on the immune response to cancers" 15 : 927-943, 2014

      5 Abuodeh Y, "Systematic review of case reports on the abscopal effect" 40 : 25-37, 2016

      6 Ishiyama H, "Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?" 10 : 196-198, 2012

      7 Okwan-Duodu D, "Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma" 38 : 119-125, 2015

      8 Eric C. Ko, "Radiotherapy and checkpoint inhibitors: a winning new combination?" SAGE Publications 10 : 175883591876824-, 2018

      9 Negi N, "Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ" 37 : 57-68, 2018

      10 Weber JS, "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial" 16 : 375-384, 2015

      11 Eggermont AM, "New drugs in melanoma: it's a whole new world" 47 : 2150-2157, 2011

      12 Eichler AF, "Multidisciplinary management of brain metastases" 12 : 884-898, 2007

      13 Franchino F, "Mechanisms and therapy for cancer metastasis to the brain" 8 : 161-, 2018

      14 Lim SY, "Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma" 123 (123): 2118-2129, 2017

      15 Wagle N, "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition" 4 : 61-68, 2014

      16 Long GV, "Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib" 36 : 667-673, 2018

      17 Golden EB, "Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial" 16 : 795-803, 2015

      18 Ott PA, "Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data" 5 : 202-, 2015

      19 Long GV, "Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma" 5 : 5694-, 2014

      20 Koller KM, "Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone" 18 : 36-42, 2017

      21 Kumari A, "Immunomodulatory effects of radiation: what is next for cancer therapy?" 12 : 239-256, 2016

      22 Muldoon LL, "Immunologic privilege in the central nervous system and the blood-brain barrier" 33 : 13-21, 2013

      23 Beaver JA, "FDA approval of nivolumab for the first-line treatment of patients with BRAF(V600) wild-type unresectable or metastatic melanoma" 23 : 3479-3483, 2017

      24 Barone A, "FDA Approval Summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma" 23 : 5661-5665, 2017

      25 Hazarika M, "FDA Approval Summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab" 23 : 3484-3488, 2017

      26 Chuk MK, "FDA Approval Summary: accelerated approval of pembrolizumab for secondline treatment of Metastatic Melanoma" 23 : 5666-5670, 2017

      27 Long GV, "Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study" 28 : 1631-1639, 2017

      28 Long GV, "Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAFmutant melanoma: a multicentre, double-blind, phase 3randomised controlled trial" 386 : 444-451, 2015

      29 Rausch MP, "Cutaneous melanoma: etiology and therapy" Codon Publications 2017

      30 Chicas-Sett R, "Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review" 9 : 5-11, 2017

      31 Ascierto PA, "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial" 17 : 1248-1260, 2016

      32 Johnson DB, "Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms" 51 : 2792-2799, 2015

      33 Brix N, "Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences" 280 : 249-279, 2017

      34 Grimaldi AM, "Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy" 3 : e28780-, 2014

      35 Siva S, "Abscopal effects of radiation therapy: a clinical review for the radiobiologist" 356 : 82-90, 2015

      36 Chandra RA, "A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab" 4 : e1046028-, 2015

      37 Hiniker SM, "A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma" 96 : 578-588, 2016

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 선정 (해외등재 학술지 평가) KCI등재
      2020-12-01 평가 등재후보로 하락 (해외등재 학술지 평가) KCI등재후보
      2015-01-01 평가 SCOPUS 등재 (기타) KCI등재
      2013-01-01 평가 등재후보 1차 FAIL (등재후보1차) KCI등재후보
      2012-04-01 평가 등재후보로 하락 (기타) KCI등재후보
      2012-01-01 평가 등재후보학술지 유지 (기타) KCI등재후보
      2011-12-30 학회명변경 영문명 : The Korean Society For Therapeutic Radiology And Oncology -> The Korean Society for Radiation Oncology KCI등재
      2011-08-22 학술지명변경 한글명 : 대한방사선종양학회지 -> Radiation oncology journal
      외국어명 : The Journal of the Korean Society for Therapeutic Radiology and Oncology -> Radiation oncology journal
      KCI등재
      2009-01-01 평가 등재 1차 FAIL (등재유지) KCI등재
      2006-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2005-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2004-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.31 0.31 0.25
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.23 0.22 0.864 0.05
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼